SAGE Therapeutics (SAGE) 'Hits It Out of the Park' with SAGE-217 Data - Cowen

Sage Therapeutics (SAGE) ~45% Upside Does Not Nearly Reflect Potential Market Opportunity - RBC

RBC Capital analyst Brian Abrahams weighed in on Sage Therapeutics (NASDAQ: SAGE) following a Q&A session hosted by management, which the analyst noted offered mostly incremental tidbits, and overall supports their comfort and enthusiasm around efficacy/safety of 217 in PPD and... More

Sage Therapeutics (SAGE) SAGE-217 Ph3 Data 'Very Impressive' - BMO

BMO Capital analyst Gary Nachman reiterated an Outperform rating and $203 price target on Sage Therapeutics (NASDAQ: SAGE) after the company reported "very impressive" Ph3 data for SAGE-217 in PPD that demonstrated strong efficacy across the board and an overall good safety... More

Sage Therapeutics (SAGE) PT Raised to $90 at Leerink Partners

Leerink Partners analyst Marc Goodman raised the price target on Sage Therapeutics (NASDAQ: SAGE) to $90.00 (from $80.00) while maintaining a Underperform rating.

Pre-Open Stock Movers 01/07: (LXFT) (LOXO) (SAGE) Higher; (PCG) (NHTC) (DXC) Lower (more...)

Today's Pre-Open Stock Movers

Axsome Therapeutics, Inc. (NASDAQ: AXSM) 189.4% HIGHER; announced that AXS-05, a novel, oral, investigational NMDA receptor antagonist with multimodal activity, met the prespecified primary endpoint and significantly improved symptoms of depression in the ASCEND Phase 2 trial in major depressive disorder (MDD). The ASCEND study is a randomized, double-blind, active-controlled, multi-center, U.S. trial, in which 80 adult patients with confirmed moderate to severe MDD were treated either with AXS-05 (45 mg dextromethorphan/105 mg bupropion), or the active comparator bupropion (105 mg), twice daily for 6 weeks.

MYnd Analytics, Inc. (Nasdaq:... More

SAGE Therapeutics (SAGE) Surges on Positive SAGE-217 Phase 3 Data

SAGE Therapeutics (NASDAQ: SAGE) is surging 34% in pre-open trade after the company reported positive top-line results from the Phase 3 ROBIN Study.

SAGE Therapeutics (SAGE) Reports SAGE-217 Meets Primary and Secondary Endpoints in Phase 3 Clinical Trial in Postpartum Depression

Sage Therapeutics (NASDAQ: SAGE) today reported top-line results from the Phase 3 ROBIN Study. This study evaluated the effect of SAGE-217 30 mg on depressive symptoms in women with postpartum depression (PPD). After two weeks of outpatient treatment, patients treated with SAGE-217 had a statistically significant improvement of 17.8 points in the Hamilton Rating Scale for Depression (HAMD-17) score, compared to 13.6 for placebo (primary endpoint, p=0.0029), with statistically significant reductions in HAMD-17 compared to placebo maintained through the end of the four-week follow-up. Remission was achieved in 45% of patients treated with SAGE-217 for two weeks as... More